NCT02672020: COMETETACTIC

The COMETE Network, Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card

Completed NA Last updated 20 September 2019

What this trial tests

NA trial testing omics identity card in Adrenal Gland Neoplasms in 448 participants. Completed in 26 March 2019.

Timeline

1 November 2015

Primary endpoint
26 March 2019

26 March 2019

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	448
Start date	1 November 2015
Primary completion	26 March 2019
Estimated completion	26 March 2019
Sites	21 locations across France

Drugs / interventions tested

• omics identity card — full drug profile →

Conditions studied

• Adrenal Gland Neoplasms — all drugs for Adrenal Gland Neoplasms →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

15 and older, any sex, with Adrenal Gland Neoplasms. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

• Malignant status
  Time frame: Up to 36 months
  Number of participants with evidence of metastases

Sponsor's own description

Malignant pheochromocytoma/paraganglioma (MPP) and adrenocortical carcinoma (ACC) are two rare cancer entities with a very unfavorable prognosis. The knowledge on these rare cancers improved thanks to the French COMETE network originally based on two clinical centers (HEGP and Cochin) well organized for clinical and biological samples collection. Over the last 10 years, the COMETE key partners deciphered molecular mechanisms of tumorigenesis and oncogenesis of these tumors and identified molecular signatures discriminating between benign and malignant cancers by integrated genomic approaches. This strategy was highly successful in delivering new diagnostic applications of genomics technologies that now appear as potentially suitable for rapid implementation in routine clinical care.

The main objective of COMETE-TACTIC is to provide an easy-to-use "identity card" of the adrenal tumors that will allow a personalized "à la carte" management of the patient and, when indicated, to the indication of the most accurate molecular targeted therapy.

We hypothesize that the improvement of MPP and ACC diagnosis and of the therapeutic options proposed to affected patients will require,

1. the transfer to routine practice and the prospective validation of the novel diagnostic and predictive biomarkers issued from recent discoveries (genetics, genomics, histological biomarkers);
2. the implementation of the translational research projects based on the COMETE collection to identify circulating diagnostic, prognostic and therapeutic genetic and metabolic biomarkers that could be used as non-invasive "liquid biopsies".

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Translational Bioinformatics Applied to the Study of Complex Diseases.
   Casotti MC, Meira DD, Alves LNR, Bessa BGO, et al · · 2023 · cited 12× · PMID 36833346 · DOI 10.3390/genes14020419
2. Biomarkers Improving Genetic and Metastatic Disease Prediction in Paraganglioma: Insights From a Prospective Study.
   Drossart T, Buffet A, Janbain A, Ottolenghi C, et al · · 2025 · cited 4× · PMID 39541377 · DOI 10.1210/clinem/dgae797